A state-level financing strategy could help Medicaid programs provide access to hepatitis C patients while still encouraging future pharmaceutical innovation.
Schaeffer Initiative researchers propose two key changes to the MA bidding process to lower prices and enhance choice for consumers.
In 2013, almost one quarter of filled pharmacy prescriptions (23%) involved a patient copayment that exceeded the average reimbursement paid by the insurer by more than $2.00.
The researchers examined copay coupon availability for the top 200 drugs (by spending) in 2014. Of these, 132 were brand drugs, and 90 of those had coupons available.
Calculations using publicly available aggregate data suggest that the United States market accounts for 64 to 78 percent of worldwide pharmaceutical profits.
The administration and lawmakers should prioritize four actions that could engender more cooperation and improve health over the long term.